ClinicalTrials.gg
RecruitingNCT07005102Updated Oct 5, 2026

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Phase 2/3 interventional study of Standard of Care and Telisotuzumab Adizutecan in Non-Squamous Non-Small Cell Lung Cancer and c-MET, sponsored by AbbVie. Recruiting at 65 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 5, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
854
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum/pemetrexed chemotherapy).

Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into 4 groups called treatment arms where 3 groups will receive 1 of 3 doses of telisotuzumab adizutecan from from the dose escalation phase with Osi, or standard of care (Osi plus chemotherapy). In the second stage participants will receive the optimal dose of telisotuzumab adizutecan, from the previous stage, with Osi, or SOC. Approximately 854 adult participants with 1L estimated glomerular filtration rate (EGFR) mut (mutated) not sufficient quantity (NSq) NSCLC will be enrolled in the study in 200 sites worldwide.

In Stage 1, during dose escalation participants will receive increasing intravenous (IV) doses of telisotuzumab adizutecan with oral Osi tablets. participants will receive 1 of 3 doses of telisotuzumab adizutecan with Osi, or standard of care (Osi plus chemotherapy). In stage 2 participants will receive the optimal dose of IV telisotuzumab adizutecanin with oral Osi tablet, or SOC. The study will run for a duration of approximately 76 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

02

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
  • c-MET

Browse trials for

Keywords

  • Non-Squamous Non-Small Cell Lung Cancer
  • Telisotuzumab Adizutecan
  • Osimertinib
  • Cisplatin
  • Carboplatin
  • Pemetrexed
  • ABBV-400
  • Stand of Care
  • Cancer
  • Chemotherapy
  • Platinum Chemotherapy
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 854 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status (PS) of 0 or 1 during the screening period and prior to dosing of study treatment on Cycle 1 Day 1.
  • Must consent to provide recently obtained formalin-fixed, paraffin-embedded (FFPE) tumor tissue (ideally collected during or after locally advanced or diagnosis) or archived tissue during screening for c-Met immunohistochemistry (IHC) testing and study stratification. c-Met IHC results are required prior to randomization.
  • Must have at least one non-irradiated per (RECIST) version 1.1. If only one measurable lesion exists, it is acceptable to be used (as a target lesion) as long as it has not been previously irradiated and as long as it has not been biopsied within 14 days of the baseline tumor assessment scans.
  • Any toxicities from prior systemic anti-cancer therapy must have resolved to (CTCAE) Grade 1 or baseline level (except for alopecia [any grade] or Grade \<= 2 peripheral neuropathy).
  • Should not have any major, life-threatening conditions and as determined by the investigator should be at least 3 months.
  • No prior estimated (EGFR) tyrosine kinase inhibitor (TKI) in the locally advanced and/or metastatic setting (except for when it is allowed on study prior to C1D1). Participants treated with prior EGFR TKI in the setting are allowed to enroll provided that >= 126 months (since last dose of e.g., adjuvant osimertinib) have passed before Cycle 1, Day 1.
  • Diagnosis of or cytologically confirmed metastatic/locally advanced non-squamous NSCLC with documented classical EGFR mutation (Exon 19 Del or Exon 21 L858R) either alone or in combination with other EGFR mutations as detected by an Food and Drug Administration (FDA)-approved or other validated test in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (sites in the US) or an accredited Laboratory (sites outside of the US) in accordance with site standard of care. A copy of the test report documenting the EGFR mutation must be available in the participant records.

Exclusion criteria

Exclusion Criteria:

  • History of interstitial lung disease (ILD), pneumonitis that required treatment with systemic , or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
  • Participants has , or participant has spinal cord compression not definitively treated with surgery or radiation.
  • History of any other than disease under study except for

    1. Malignancy treated with curative intent and with no known active disease present for 2 years before the first dose of study treatment and felt to be at low risk for recurrence by investigator.
    2. Successfully treated nonmelanoma skin cancer.
    3. Localized carcinoma in situ of the cervix.
    4. Breast Cancer; lobular carcinoma in situ or ductal carcinoma in situ that is considered completely cured.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
854 participants (estimated)

Study arms

  • Experimental
    Stage 1: Escalation Telisotuzumab Adizutecan + Osimertinib

    Participants will receive increasing doses of telisotuzumab adizutecan with osimertinib (Osi), as part of the approximately 76 month study duration.

    Drug: Telisotuzumab Adizutecan · Drug: Osimertinib (Osi)

  • Experimental
    Stage 1: Expansion Telisotuzumab Adizutecan Dose A + Osi

    Participants will receive telisotuzumab adizutecan dose A with Osi, as part of the approximately 76 month study duration.

    Drug: Telisotuzumab Adizutecan · Drug: Osimertinib (Osi)

  • Experimental
    Stage 1: Expansion Telisotuzumab Adizutecan Dose B + Osi

    Participants will receive telisotuzumab adizutecan dose B with Osi, as part of the approximately 76 month study duration.

    Drug: Telisotuzumab Adizutecan · Drug: Osimertinib (Osi)

  • Experimental
    Stage 1: Expansion Telisotuzumab Adizutecan Dose C + Osi

    Participants will receive telisotuzumab adizutecan dose C with Osi, as part of the approximately 76 month study duration.

    Drug: Telisotuzumab Adizutecan · Drug: Osimertinib (Osi)

  • Experimental
    Stage 1: Expansion Osi + Chemotherapy + Pemetrexed

    Participants will receive Osi with chemotherapy followed by Osi with pemetrexed, as part of the approximately 76 month study duration.

    Drug: Osimertinib (Osi) · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Stage 2: Standared of Care (SOC)

    Participants will receive SOC, as part of the approximately 76 month study duration.

    Drug: Standard of Care · Drug: Osimertinib (Osi)

  • Experimental
    Stage 2: Optimized Telisotuzumab Adizutecan + Osi

    Participants will receive the optimized dose of telisotuzumab adizutecan with Osi, as part of the approximately 76 month study duration.

    Drug: Telisotuzumab Adizutecan · Drug: Osimertinib (Osi)

Interventions

06

What researchers measure

Primary outcomes

  1. Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on RECIST version 1.1.

    Time frame: Up to Approximately 76 Months

  2. Stage 2: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1.

    PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per BICR based on RECIST version 1.1 or death from any cause, whichever occurs earlier.

    Time frame: Up to Approximately 76 Months

  3. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 76 Months

Secondary outcomes

  1. Stage 1: PFS based on BICR assessment per RECIST version 1.1.

    PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per BICR based on RECIST version 1.1 or death from any cause, whichever occurs earlier.

    Time frame: Up to Approximately 76 Months

  2. Stage 1: Duration of response (DoR) based on BICR assessment per RECIST version 1.1.

    DOR is defined as the time from the first documented CR or PR per BICR to the first occurrence of radiographic progression per RECIST version 1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.

    Time frame: Up to Approximately 76 Months

  3. Stage 1: Disease control rate (DC) based on BICR assessment per RECIST version 1.1.

    DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) for at least 12 weeks following randomization date based on RECIST version 1.1, as determined by the BICR.

    Time frame: Up to Approximately 76 Months

  4. Stage 1: Overall Survival

    OS is defined as the time from participant's randomization date to the event of death from any cause.

    Time frame: Up to Approximately 76 Months

  5. Stage 2: Overall Survival

    OS is defined as the time from participant's randomization date to the event of death from any cause.

    Time frame: Up to Approximately 76 Months

  6. Stage 2: OR based on BICR assessment per RECIST version 1.1.

    OR is defined as confirmed CR or confirmed PR per BICR based on RECIST version 1.1.

    Time frame: Up to Approximately 76 Months

  7. Stage 2: DoR based on BICR assessment per RECIST version 1.1.

    DOR is defined as the time from the first documented CR or PR per BICR to the first occurrence of radiographic progression per RECIST version 1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.

    Time frame: Up to Approximately 76 Months

  8. Stage 2: DC based on BICR assessment per RECIST version 1.1.

    DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST version 1.1, as determined by the BICR.

    Time frame: Up to Approximately 76 Months

  9. Stage 2: Change from baseline at Week 12 in physical functioning as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

    The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).

    Time frame: Up to Approximately 76 Months

  10. Stage 2: Change from baseline at Week 12 in key lung cancer symptoms as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 (EORTC QLQ-LC13)

    The EORTC QLQ-LC13 is a lung cancer specific module and consists of 13 questions assessing lung cancer-associated symptoms and treatment-related effects, including one multiple-item scale to assess dyspnea and a series of single items assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain, and pain medication. Each item is assessed on a Likert scale from 1 (not at all) to 4 (very much).

    Time frame: Up to Approximately 76 Months

  11. Stage 2: Change from baseline at Week 12 in GHS/QoL as measured by the EORTC QLQ-C30.

    The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).

    Time frame: Up to Approximately 76 Months

07

Study locations

63 of 65 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2036, 135 months after the start.

Of 47 phase 2/3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 90. This study's planned 135 months is above that.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2031 → Nov 2036, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 5, 2025
StartActual
Aug 3, 2025
Primary completionEst.
Nov 2036was Dec 2031
CompletionEst.
Nov 2036
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added, 4 sites removed. Princess Margaret Cancer Centre /ID# 274845 is now Active, not recruiting
Show 16 added (6 China, 5 United States, 2 Australia, 2 Italy, 1 Spain)
  • Ironwood Cancer and Research Centers - Chandler /ID# 275443 · Chandler, United States
  • City of Hope National Medical Center /ID# 282241 · Duarte, United States
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734 · Irvine, United States
  • UCLA - Santa Monica /ID# 276816 · Santa Monica, United States
  • City Of Hope - Upland /ID# 284650 · Upland, United States
  • The Queen Elizabeth Hospital /ID# 275719 · Woodville South, Australia
  • St John of God Murdoch Hospital /ID# 275700 · Murdoch, Australia
  • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 275631 · Beijing, China
  • Fujian Province Cancer Hospital /ID# 274913 · Fuzhou, China
  • The First Affiliated Hospital Of Guangzhou Medical University /ID# 274914 · Guangzhou, China
  • The First affiliated hospital of Nanchang University /ID# 275257 · Nanchang, China
  • Shanghai Chest Hospital /ID# 275273 · Shanghai, China
  • West China Hospital of Sichuan University /ID# 274946 · Chengdu, China
  • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 277808 · Perugia, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 280103 · Roma, Italy
  • Instituto Valenciano de Oncologia /ID# 275471 · Valencia, Spain
Show 4 removed
  • Ironwood Cancer and Research Centers - Chandler II /ID# 275443 · Chandler, United States
  • The Queen Elizabeth Hospital /ID# 275719 · Woodville, Australia
  • St John Of God Murdoch Hospital /ID# 275700 · Murdoch, Australia
  • Instituto Valenciano de Oncología /ID# 275471 · Valencia, Spain
Oct 5, 2026
Primary completion
Dec 2031→Nov 2036
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    16 sites added, 4 sites removed. Princess Margaret Cancer Centre /ID# 274845 is now Active, not recruiting
    Show 16 added (6 China, 5 United States, 2 Australia, 2 Italy, 1 Spain)
    • Ironwood Cancer and Research Centers - Chandler /ID# 275443 · Chandler, United States
    • City of Hope National Medical Center /ID# 282241 · Duarte, United States
    • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734 · Irvine, United States
    • UCLA - Santa Monica /ID# 276816 · Santa Monica, United States
    • City Of Hope - Upland /ID# 284650 · Upland, United States
    • The Queen Elizabeth Hospital /ID# 275719 · Woodville South, Australia
    • St John of God Murdoch Hospital /ID# 275700 · Murdoch, Australia
    • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 275631 · Beijing, China
    • Fujian Province Cancer Hospital /ID# 274913 · Fuzhou, China
    • The First Affiliated Hospital Of Guangzhou Medical University /ID# 274914 · Guangzhou, China
    • The First affiliated hospital of Nanchang University /ID# 275257 · Nanchang, China
    • Shanghai Chest Hospital /ID# 275273 · Shanghai, China
    • West China Hospital of Sichuan University /ID# 274946 · Chengdu, China
    • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 277808 · Perugia, Italy
    • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 280103 · Roma, Italy
    • Instituto Valenciano de Oncologia /ID# 275471 · Valencia, Spain
    Show 4 removed
    • Ironwood Cancer and Research Centers - Chandler II /ID# 275443 · Chandler, United States
    • The Queen Elizabeth Hospital /ID# 275719 · Woodville, Australia
    • St John Of God Murdoch Hospital /ID# 275700 · Murdoch, Australia
    • Instituto Valenciano de Oncología /ID# 275471 · Valencia, Spain
    Primary completion Dec 2031→Nov 2036
    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07005102
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Aug 3, 2025
Primary completion
Nov 2036 (estimated)
Completion
Nov 2036 (estimated)
Last update
Oct 5, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telisotuzumab adizutecan

Start the discussion